We are a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade hypochlorous acid-based (HOCl) therapeutics designed to prevent and treat infection in invasive applications.
Our lead drug candidate, RUT58-60, is a broad spectrum anti-infective that we are developing for the prevention and treatment of infection in surgical and trauma procedures. We are focusing RUT58-60 for use initially in abdominal surgery due to the large addressable market, high rate of post-surgical infection associated with abdominal surgery, the high-impact opportunity that abdominal surgery offers us in the clinical trial setting to expose multiple internal organs to RUT58-60 at one time, and feedback from surgeons identifying post-surgical infection in abdominal surgery (relative to other surgeries) as a significant unmet medical need.
Ruthigen, Inc. (“Ruthigen”) was incorporated under the laws of the State of Nevada on January 18, 2013 as a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (“Oculus”). Ruthigen intends to spin-off from Oculus and independently fund research and development and commercialization of RUT58-60 and future drug development candidates. Ruthigen is developing RUT58-60, a hypochlorous acid-based solution, with two to four times the concentration of Microcyn® based products manufactured by Oculus while meeting the stringent drug requirements mandated by FDA including but not limited to sterility, stability, safety and efficacy. RUT58-60 contains small molecule stabilizers including magnesium and no hypochlorite and is intended for use during invasive procedures with direct exposure to internal tissue and organs. RUT58-60 uses design elements that management believes will allow the product to be evaluated and reviewed as a biopharmaceutical agent, as opposed to a medical device.
We have entered into a series of agreements with Oculus that will govern our technology license, exclusive rights to develop and commercialize our drug candidate and future hypochlorous-acid based drug candidates in the United States, Canada, the European Union and Japan (the “Territory”), and the separation of the companies.
2455 Bennett Valley Road, Suite C116
Santa Rosa, California 95404